B Cell Induction in Pediatric Lung Transplantation
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study ID
- NCT02266888
- Phase
- PHASE2
- Status
- Completed
Conditions
- Lung Transplant
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab (Rituxan®) — BIOLOGICAL2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
- Placebo — BIOLOGICALPlacebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
Study Details
In this study, doctors are trying to see if a study drug called rituximab (Rituxan®) will lower the number of B cells in the body. Doctors are also trying to see if decreasing B cells with rituximab (Rituxan®) can prevent injury to the transplanted lung. This treatment has been studied in other types of solid organ transplants.
Key Dates
- Start date
- Jan 22, 2015
- Status verified
- Oct 2021
- Primary completion
- Jun 30, 2019
- Completion
- Jun 30, 2019
Study Design
- Enrollment
- 45 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Rituximab InductionRituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
- Placebo Comparator: Placebo InductionPlacebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
Primary Outcome Measure
Earliest Time to Any of the Following Events: Chronic Allograft Dysfunction, Listed for Retransplant or Death [ Time Frame: Up to 35 months post-transplant ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94305 | - |
| Children's Hospital Boston | Boston | Massachusetts | 02115 | - |
| Washington University | St Louis | Missouri | 63110 | - |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | - |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | - |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
| Texas Children's Hospital | Houston | Texas | 77030 | - |
Find similar trials in Palo Alto, CA
Related Studies
- A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung TransplantationRecruiting · Mayo Clinic · Louisville, Kentucky
- Tocilizumab in Lung TransplantationPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Phoenix, Arizona
- TEE and Dysphagia in Lung TransplantationRecruiting · University of California, Los Angeles · Los Angeles, California
- Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California